Thyroid Disease

RNase A (Bovine pancreatic RNase) is a widely used Endonuclease in DNA purification by specifically hydrolyzing cytosine or uracil residues of RNA. RNase A degrades the RNA in the RNA/DNA duplex. RNase A catalyses the breakdown of 3',5'-phosphodiester linkages of single stranded RNA. RNase A family members in organisms are tightly involved in various physiological and pathological processes including cell growth and development, proliferation, differentiation and migration. Dysregulation of RNase A activity or expression level is closely related to pancreatic, ovarian, bladder and thyroid cancer. RNase A has tumor cell-killing ability. RNase A, Bovine Pancreas (DNase & Protease Free) is RNase A derived from bovine pancreas and does not contain DNase or protease.

Latanoprost lactone diol is a small organic molecule derived from Prostaglandin F2α (HY-12956), serving as a key synthetic intermediate and inactive metabolism-related form of Latanoprost (HY-B0577). Latanoprost lactone diol is significantly upregulated in hypothyroid rats, and its level can be reversed by crude polysaccharide, lactone and oligosaccharide fractions from the rhizome of Atractylodis macrocephalae. Latanoprost lactone diol can be used in studies related to hypothyroidism.

PF-04217903 phenolsulfonate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a K_i value of 4.8 nM and a K_d value of 4.5 nM. PF-04217903 phenolsulfonate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 phenolsulfonate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 phenolsulfonate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 phenolsulfonate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 phenolsulfonate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis).

RET-IN-36 is an orally active RET kinase inhibitor. RET-IN-36 overcomes gatekeeper and solvent front resistance mutations and inhibits the proliferation of cells expressing RET^G810C and RET^V804M mutants by suppressing RET phosphorylation and SHC downstream signaling. RET-IN-36 can be used for research on RET-mutant cancers, medullary thyroid cancer, papillary thyroid cancer, and non-small cell lung cancer.

Bovine Thyrotropin is a pituitary glycoprotein hormone derived from cattle, with identical properties to thyroid-stimulating hormone (TSH). Bovine Thyrotropin stimulates thyroid function and is used to differentiate between primary and secondary hypothyroidism. Bovine Thyrotropin can induce increased radioactive iodine uptake in metastatic thyroid cancer lesions, and long-term administration leads to the production of neutralizing antibodies and hemagglutinating antibodies. Bovine Thyrotropin is applicable to research related to metastatic thyroid cancer.

YW-N-7 TFA is a PROTAC degrader targeting RET kinase, with an IC₅₀ of 8.4 nM. YW-N-7 TFA inhibits RET kinase activity and induces proteasome-mediated degradation of RET fusion proteins, while enhancing the anti-tumor activity of Selpercatinib (LOXO-292) (HY-114370). YW-N-7 TFA can be used in the research of cancers associated with RET gene abnormalities, including medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer.

OSU-53 is an orally active AMPK activator and mTOR inhibitor, with an IC₅₀ of 0.3 μM for AMPK, an EC₅₀ of 2-5 μM for AMPK, and an IC₅₀ of 8.23 μM for mTOR. OSU-53 inhibits the Akt signaling pathway, directly activates AMPK by binding to its autoinhibitory domain, reduces IKKβ-mediated phosphorylation of Foxo3a, blocks Akt-mediated phosphorylation of MDM2, and promotes the nuclear localization and stabilization of Foxo3a, while directly inhibiting mTOR. OSU-53 inhibits epithelial-mesenchymal transition (EMT), induces epithelial phenotype, suppresses invasion and metastasis, induces autophagy, inhibits the activation of ERK and Akt, reduces the secretion of nitric oxide and proinflammatory cytokines, and inhibits the migration of MDSC; at high doses, it induces MDSC apoptosis, attenuates the immunosuppressive effect of MDSC, reduces MDSC levels, and blocks incision-induced mechanical hyperalgesia. OSU-53 can be used in studies related to breast cancer, prostate cancer, thyroid cancer, melanoma and postoperative pain.

[U-¹⁵N]-TSH is the ¹⁵N-labeled TSH. Thyroid-stimulating hormone (TSH) dysfunction is closely associated with primary and secondary thyroid disorders and serves as a key biomarker for the diagnosis and classification of thyroid diseases. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.

[U-¹⁵N]-TG-domain4 is the ¹⁵N-labeled TG-domain4. TG-domain 4, a key functional region of thyroglobulin (TG), is a significant biomarker associated with monitoring thyroid cancer recurrence, autoimmune thyroid diseases, and thyroid dysfunction. This isotope-labeled form can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.

[U-¹⁵N]-TG-domain2 is the ¹⁵N-labeled TG-domain2. Thyroglobulin (TG-domain 2) is involved in iodine binding and hormone modification, serving as an important biomarker for thyroid cancer, autoimmune thyroiditis, and thyroid dysfunction. This isotope-labeled form can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.

PROTAC RET Degrader 2 is a RET degrader with a target IC₅₀ of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma.

RET-IN-34 is a RET inhibitor with an IC₅₀ of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma.

RET-IN-33 is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC₅₀ values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC₅₀ 0.73 nM), V804L (IC₅₀ 0.36 nM), Y806H (IC₅₀ 0.74 nM) and M918T (IC₅₀ 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC₅₀ of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer.

MEAP (2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine) is a NEDD9-STAT3 modulator. MEAP disrupts NEDD9-STAT3 interaction, driving STAT3 Y705 dephosphorylation. MEAP induces G₂/M phase arrest. MEAP can be used for the research of anaplastic thyroid cancer.

RET-IN-32 is an orally active RET inhibitor with IC₅₀ values of 0.285, 4.602 and 103.5 nM against wild-type, V804M and G810S mutant forms, respectively. RET-IN-32 inhibits the autophosphorylation of Tyr1062. RET-IN-32 completely suppresses tumor growth induced by BAF3-KIF3B-RET-WT xenografts. RET-IN-32 can be used in the research of thyroid cancer and lung cancer.

Salcolin B is a natural flavonoid.

(rel)-Salcolin A is a flavonoid lignan compound with anticancer, anti-inflammatory, and neuroprotective activities. (rel)-Salcolin A has IC₅₀ values ??of 66.69 μM and 56.12 μM against anaplastic thyroid carcinoma cells (HTH83) and papillary thyroid carcinoma cells (TPC1), respectively. (rel)-Salcolin A also inhibits LPS-induced NO production with an IC₅₀ of 14.65 μM. (rel)-Salcolin A exerts its effects by inducing necroptosis in thyroid cancer cells, inhibiting the production of the inflammatory factor NO, and protecting against glutamate-induced neuronal cell damage, with a neuroprotective E₅₀ of 47.44 μM. (rel)-Salcolin A can be used in research related to thyroid cancer, anti-inflammation, and neuroprotection. (rel)-Salcolin A can be naturally extracted from the leaves of Casearia arborea and the stems of Zea mays (corn).

Diosbulbin I is a furan-type nor-diterpenoid compound that can be naturally extracted from the tubers of Dioscorea bulbifera L. Dioscorea bulbifera L. is traditionally used to research thyroid diseases and tumors.

ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.

ZW-6-052 (compound 20), the derivative of ZW-18-116 (HY-180550), is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-6-052 induces degradation of TMP3-TRKA in KM12 mouse xenograft models. ZW-6-052 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.